ADC CDMO

Antibody-drug conjugates (ADCs) represent a rapidly advancing class of targeted therapeutics that combine the specificity of monoclonal antibodies with the potent activity of cytotoxic payloads through specialized linker technologies. The development of ADC products requires coordinated expertise across molecular design, conjugation processes, analytical characterization, manufacturing, and quality evaluation. Protheragen provides integrated ADC CDMO services to support antibody-drug conjugate programs throughout the development lifecycle.

Overview of ADC CDMO

Antibody-drug conjugates (ADCs) are a class of targeted therapeutic molecules that combine the selective targeting capability of monoclonal antibodies with the potent cytotoxic activity of small-molecule payloads through chemical linkers. By enabling selective delivery of therapeutic payloads to target cells, ADCs have become an important platform in the development of next-generation precision medicines, particularly in oncology.

The development and manufacturing of ADCs involve highly integrated biological, chemical, and analytical processes. Unlike conventional biologics, ADCs consist of multiple functional components, including antibodies, linkers, and payloads, and their quality and performance are influenced by factors such as conjugation efficiency, drug-to-antibody ratio (DAR), molecular stability, purity, aggregation, and biological activity.

ADC CDMO services provide comprehensive support throughout the ADC development lifecycle, covering ADC process development, conjugation optimization, analytical characterization, formulation development, drug substance manufacturing, drug product manufacturing, and quality control testing. An integrated ADC CDMO platform enables consistent process control, reliable product quality assessment, and efficient transition of ADC candidates from early development stages to clinical and commercial manufacturing.

Fig.1 The Development and Mechanism of ADCs in Oncology Treatment. (Wu D, et al., 2025)

Our Services

Protheragen provides comprehensive ADC CDMO services covering development, analytical support, manufacturing, and quality control. Our integrated platform helps partners address the complex requirements associated with ADC programs and accelerate development progress.

Applications

1. Oncology ADC Development

Supporting targeted cancer therapeutics through integrated ADC development and manufacturing solutions.

Applications:

2. Next-Generation ADC Platforms

Supporting innovative ADC formats and advanced conjugation strategies.

Applications:

3. Clinical-Stage ADC Programs

Supporting ADC candidates entering clinical development.

Applications:

4. ADC Biosimilar & Comparability Programs

Supporting analytical evaluation and similarity assessment of ADC products.

Applications:

ADC Analytical & Manufacturing Challenges

The development and manufacturing of antibody-drug conjugates involve complex biological and chemical processes that require precise control throughout the product lifecycle. Unlike conventional biologics, ADCs consist of multiple functional components, including antibodies, linkers, and payloads, where variations in conjugation, molecular structure, and process conditions can significantly impact product quality and performance.

Successful ADC programs require comprehensive analytical strategies and robust manufacturing approaches to characterize critical quality attributes, optimize process parameters, maintain product consistency, and support successful clinical development. An experienced ADC CDMO partner helps address these challenges through integrated development, analytical, manufacturing, and quality control solutions.

Why Choose Protheragen

• Integrated ADC Development Expertise

Providing coordinated support across ADC development, analytical characterization, manufacturing, and quality control.

• Comprehensive Analytical Capabilities

Supporting detailed evaluation of ADC molecular characteristics and critical quality attributes.

• Flexible Development and Manufacturing Support

Supporting ADC programs from early-stage development to clinical and commercial manufacturing requirements.

• Quality-Focused Approach

Maintaining product consistency through robust analytical strategies, controlled manufacturing processes, and comprehensive quality evaluation.

The development of ADC therapeutics requires multidisciplinary expertise and reliable development support across every stage of the product lifecycle. Protheragen provides integrated ADC CDMO solutions to help partners advance ADC candidates from early development through manufacturing and quality evaluation. With comprehensive capabilities in ADC development, analytical support, manufacturing services, and quality control, we support the efficient progression of antibody-drug conjugate programs toward clinical and commercial success. Contact us to explore customized ADC CDMO solutions designed to support your antibody-drug conjugate program from development to manufacturing.